Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 38 member 8 (SLC38A8), also known as SNAT8, is a sodium-coupled neutral amino acid transporter belonging to the SLC38 family[5][1][3]. It is a transmembrane protein with eleven transmembrane domains, transporting amino acids—including L-glutamine, L-alanine, L-histidine, L-aspartate, and L-arginine—into neurons, with sodium dependence[1][5][3]. SLC38A8 is classified as a system A transporter and is crucial for maintaining neuronal amino acid pools and regulating the glutamine/glutamate (GABA) cycle in the brain, suggesting a foundational role in neurotransmission and brain metabolism[1][3]. Mutations in SLC38A8 cause foveal hypoplasia 2, pathologic nystagmus, and related visual system development disorders[5]. While functionally characterized in neuronal context and associated with developmental diseases, there are currently no known drugs that specifically target SLC38A8 for therapeutic purposes[5][1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 38 member 8 (SLC38A8).